Dividends Inside Welcome to Dividends Inside
Welcome to Dividends Inside!
The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.
Welcome to Dividends Inside!
The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.
Scorpius Holdings Inc.
SCPX
$0.00 (+ $0.00 + 0.00%)
Last updated: Previous Close (2026-05-19)
About the Company
Scorpius Holdings Inc. is a diversified conglomerate primarily focused on strategic investments across multiple sectors. Its core purpose is to identify and capitalize on lucrative opportunities within emerging and established industries. The company holds a prominent position in sectors such as renewable energy, technology, and real estate, aiming to foster sustainable growth and innovation. Scorpius Holdings strategically acquires and manages a portfolio of dynamic businesses, leveraging synergies and expertise to enhance asset value and operational efficiencies. By diversifying its investment portfolio, it mitigates risk and optimizes returns. The corporation plays a significant role in the financial market, contributing to industrial advancements and economic growth through its varied holdings. With a commitment to responsible investing, Scorpius Holdings ensures that its activities align with environmental, social, and governance (ESG) criteria, reflecting its dedication to ethical business practices in the global marketplace. This strategic focus makes Scorpius Holdings Inc. a notable player in shaping future-driven industries.
Price History
Latest News for SCPX
Tivic Acquires Ready-to-Scale cGMP Manufacturing and Development Assets to Accelerate Commercialization of Entolimod; Tivic Growth Backed By $90M+ Financing Package
Acquisition creates additional near-term revenue opportunities from newly formed Contract Development and Manufacturing Organization (CDMO) subsidiary, Velocity Bioworks™ Financing led by 3i, LP includes $16M debt financing for the purchase ...
Tivic Health Enters GMP Manufacturing Validation Agreement with Scorpius BioManufacturing in Preparation for FDA Submission
FREMONT, Calif., May 14, 2025--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today it has entered a definitive agreement with Scorpius BioManufacturing to complete the GMP manufacturing validation of the lead candidate from its TLR5 program, Entolimod™, for treatment of Acute Radiation Syndrome, or ARS, in preparation for filing a Biological Licensing application, or BLA, with the U.S. Food & Drug Administration.
Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia
Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX , May 05, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (OTC: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization ("CDMO”), today provided a corporate update highlighting key strategic initiatives, including cost optimization measures expected to yield over $6 million in annualized
Scorpius Holdings Provides 2024 Year-End Business Update; Implements Strategic Cost Reductions and Operational Streamlining
SAN ANTONIO, April 30, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (OTC: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization ("CDMO”), today provided strategic, financial, and operational updates for the year ended December 31, 2024. Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, "The current biotech funding environment has created real headwinds for many of our clients, particularly when it comes to advancing drug development and clinic
Scorpius Holdings Receives NYSE American Notice of Delisting and Reports Plans to Appeal
San Antonio, TX, April 21, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today reported that it received notice from the NYSE American LLC (“NYSE American” or the “Exchange”) of its determination to commence delisting proceedings of the Company’s common stock from the exchange pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low-selling pr